Key statistics
As of last trade, Avalo Therapeutics Inc (C6K0:DEU) traded at 8.44, 18,866.29% above the 52 week low of 0.0445 set on Dec 29, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.64 |
---|---|
High | 8.78 |
Low | 8.08 |
Bid | 8.18 |
Offer | 8.78 |
Previous close | 8.90 |
Average volume | 115.22 |
---|---|
Shares outstanding | 9.68m |
Free float | 9.51m |
P/E (TTM) | -- |
Market cap | 87.43m USD |
EPS (TTM) | -63.82 USD |
Data delayed at least 15 minutes, as of Oct 09 2024.
More ▼
Announcements
- Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
- Avalo Announces Participation in September Investor Conferences
- Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
- Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
- Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
- Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
- Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
- Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
- Avalo Reports 2023 Financial Results and Provides Business Updates
More ▼